Bristol-Myers Squibb Co. reported a better-than-expected 6% rise in fourth-quarter revenue and a 9% rise in adjusted earnings, benefiting from a portfolio of cancer therapies the company said it was aiming to expand.

Bristol said it would be conducting four clinical trials this year of its closely watched experimental cancer treatment nivolumab that could be used to apply for regulatory approval for lung cancer if the drug is shown...